These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

337 related articles for article (PubMed ID: 26385374)

  • 1. Carfilzomib combined with suberanilohydroxamic acid (SAHA) synergistically promotes endoplasmic reticulum stress in non-small cell lung cancer cell lines.
    Hanke NT; Garland LL; Baker AF
    J Cancer Res Clin Oncol; 2016 Mar; 142(3):549-60. PubMed ID: 26385374
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Proteasome inhibition sensitizes non-small cell lung cancer to histone deacetylase inhibitor-induced apoptosis through the generation of reactive oxygen species.
    Denlinger CE; Rundall BK; Jones DR
    J Thorac Cardiovasc Surg; 2004 Nov; 128(5):740-8. PubMed ID: 15514602
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Combined inhibition of EZH2 and histone deacetylases as a potential epigenetic therapy for non-small-cell lung cancer cells.
    Takashina T; Kinoshita I; Kikuchi J; Shimizu Y; Sakakibara-Konishi J; Oizumi S; Nishimura M; Dosaka-Akita H
    Cancer Sci; 2016 Jul; 107(7):955-62. PubMed ID: 27116120
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Enhancement of cisplatin cytotoxicity by SAHA involves endoplasmic reticulum stress-mediated apoptosis in oral squamous cell carcinoma cells.
    Suzuki M; Endo M; Shinohara F; Echigo S; Rikiishi H
    Cancer Chemother Pharmacol; 2009 Nov; 64(6):1115-22. PubMed ID: 19280190
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Carfilzomib demonstrates broad anti-tumor activity in pre-clinical non-small cell and small cell lung cancer models.
    Baker AF; Hanke NT; Sands BJ; Carbajal L; Anderl JL; Garland LL
    J Exp Clin Cancer Res; 2014 Dec; 33(1):111. PubMed ID: 25612802
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Ricolinostat (ACY-1215) induced inhibition of aggresome formation accelerates carfilzomib-induced multiple myeloma cell death.
    Mishima Y; Santo L; Eda H; Cirstea D; Nemani N; Yee AJ; O'Donnell E; Selig MK; Quayle SN; Arastu-Kapur S; Kirk C; Boise LH; Jones SS; Raje N
    Br J Haematol; 2015 May; 169(3):423-34. PubMed ID: 25709080
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Histone deacetylase inhibitor, suberoylanilide hydroxamic acid (SAHA), enhances anti-tumor effects of the poly (ADP-ribose) polymerase (PARP) inhibitor olaparib in triple-negative breast cancer cells.
    Min A; Im SA; Kim DK; Song SH; Kim HJ; Lee KH; Kim TY; Han SW; Oh DY; Kim TY; O'Connor MJ; Bang YJ
    Breast Cancer Res; 2015 Mar; 17():33. PubMed ID: 25888415
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Gambogic Acid Shows Anti-Proliferative Effects on Non-Small Cell Lung Cancer (NSCLC) Cells by Activating Reactive Oxygen Species (ROS)-Induced Endoplasmic Reticulum (ER) Stress-Mediated Apoptosis.
    Zhu M; Jiang Y; Wu H; Shi W; Lu G; Cong D; Liu K; Song S; Ren J
    Med Sci Monit; 2019 May; 25():3983-3988. PubMed ID: 31138775
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Characterization of carfilzomib-resistant non-small cell lung cancer cell lines.
    Hanke NT; Imler E; Marron MT; Seligmann BE; Garland LL; Baker AF
    J Cancer Res Clin Oncol; 2018 Jul; 144(7):1317-1327. PubMed ID: 29766327
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Synergistic interaction of the histone deacetylase inhibitor SAHA with the proteasome inhibitor bortezomib in mantle cell lymphoma.
    Heider U; von Metzler I; Kaiser M; Rosche M; Sterz J; Rötzer S; Rademacher J; Jakob C; Fleissner C; Kuckelkorn U; Kloetzel PM; Sezer O
    Eur J Haematol; 2008 Feb; 80(2):133-42. PubMed ID: 18005386
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Suberoylanilide hydroxamic acid combined with gemcitabine enhances apoptosis in non-small cell lung cancer.
    Rundall BK; Denlinger CE; Jones DR
    Surgery; 2005 Aug; 138(2):360-7. PubMed ID: 16153448
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Suberoylanilide hydroxamic acid, an inhibitor of histone deacetylase, enhances radiosensitivity and suppresses lung metastasis in breast cancer in vitro and in vivo.
    Chiu HW; Yeh YL; Wang YC; Huang WJ; Chen YA; Chiou YS; Ho SY; Lin P; Wang YJ
    PLoS One; 2013; 8(10):e76340. PubMed ID: 24130769
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Class IIa HDAC inhibition enhances ER stress-mediated cell death in multiple myeloma.
    Kikuchi S; Suzuki R; Ohguchi H; Yoshida Y; Lu D; Cottini F; Jakubikova J; Bianchi G; Harada T; Gorgun G; Tai YT; Richardson PG; Hideshima T; Anderson KC
    Leukemia; 2015 Sep; 29(9):1918-27. PubMed ID: 25801913
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Vorinostat synergizes with EGFR inhibitors in NSCLC cells by increasing ROS via up-regulation of the major mitochondrial porin VDAC1 and modulation of the c-Myc-NRF2-KEAP1 pathway.
    Leone A; Roca MS; Ciardiello C; Terranova-Barberio M; Vitagliano C; Ciliberto G; Mancini R; Di Gennaro E; Bruzzese F; Budillon A
    Free Radic Biol Med; 2015 Dec; 89():287-99. PubMed ID: 26409771
    [TBL] [Abstract][Full Text] [Related]  

  • 15. SAHA, a HDAC inhibitor, has profound anti-growth activity against non-small cell lung cancer cells.
    Komatsu N; Kawamata N; Takeuchi S; Yin D; Chien W; Miller CW; Koeffler HP
    Oncol Rep; 2006 Jan; 15(1):187-91. PubMed ID: 16328054
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Histone deacetylase inhibitor enhances sensitivity of non-small-cell lung cancer cells to 5-FU/S-1 via down-regulation of thymidylate synthase expression and up-regulation of p21(waf1/cip1) expression.
    Noro R; Miyanaga A; Minegishi Y; Okano T; Seike M; Soeno C; Kataoka K; Matsuda K; Yoshimura A; Gemma A
    Cancer Sci; 2010 Jun; 101(6):1424-30. PubMed ID: 20384633
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Proteasome inhibitor carfilzomib interacts synergistically with histone deacetylase inhibitor vorinostat in Jurkat T-leukemia cells.
    Gao M; Gao L; Tao Y; Hou J; Yang G; Wu X; Xu H; Tompkins VS; Han Y; Wu H; Zhan F; Shi J
    Acta Biochim Biophys Sin (Shanghai); 2014 Jun; 46(6):484-91. PubMed ID: 24801128
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Vorinostat, a histone deacetylase (HDAC) inhibitor, promotes cell cycle arrest and re-sensitizes rituximab- and chemo-resistant lymphoma cells to chemotherapy agents.
    Xue K; Gu JJ; Zhang Q; Mavis C; Hernandez-Ilizaliturri FJ; Czuczman MS; Guo Y
    J Cancer Res Clin Oncol; 2016 Feb; 142(2):379-87. PubMed ID: 26314218
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Combined treatment with SAHA, bortezomib, and clarithromycin for concomitant targeting of aggresome formation and intracellular proteolytic pathways enhances ER stress-mediated cell death in breast cancer cells.
    Komatsu S; Moriya S; Che XF; Yokoyama T; Kohno N; Miyazawa K
    Biochem Biophys Res Commun; 2013 Jul; 437(1):41-7. PubMed ID: 23792097
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Decursin enhances TRAIL-induced apoptosis through oxidative stress mediated- endoplasmic reticulum stress signalling in non-small cell lung cancers.
    Kim J; Yun M; Kim EO; Jung DB; Won G; Kim B; Jung JH; Kim SH
    Br J Pharmacol; 2016 Mar; 173(6):1033-44. PubMed ID: 26661339
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.